title: Implantable porous gelatin microspheres sustained release of bFGF and improved its neuroprotective effect on rats after spinal cord injury.
abstract: In this study, porous gelatin microspheres (GMSs) were constructed to improve the neuroprotective effect of basic fibroblast growth factor (bFGF) on spinal cord injury. GMSs were prepared by a W/O emulsion template, followed by cross-linking, washing and drying. The particle sizes and surface porosity of the blank GMSs were carefully characterized by scan electronic microscopy. The blank GMSs have a mean particle size of 35μm and theirs surface was coarse and porous. bFGF was easily encapsulated inside the bulk GMSs through diffusion along the porous channel. 200μg of bFGF was completely encapsulated in 100mg of GMSs. The bFGF-loaded GMSs displayed a continuous drug release pattern without an obvious burst release over two weeks in vitro. Moreover, the therapeutic effects of bFGF-loaded GMSs were also evaluated in spinal cord injury rat model. After implantation of bFGF-loaded GMSs, the recovery of the motor function of SCI rats were evaluated by behavioral score and foot print experiment. The motor function of SCI rats treated with bFGF-loaded GMSs was more obvious than that treated with free bFGF solution (P<0.05). At the 28th days after treatment, rats were sacrificed and the injured spinal were removed for histopathological and apoptosis examination. Compared with treatment with free bFGF solution, treatment with bFGF-loaded GMSs resulted in a less necrosis, less infiltration of leukocytes, and a reduced the cavity ratio and less apoptotic cells in injured spinal(P<0.01), indicating its better therapeutic effect. Implantable porous GMSs may be a potential carrier to deliver bFGF for therapy of spinal cord injury.
authors.affiliation: Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
authors.forename: Li
authors.initials: L
authors.lastname: Lan
authors.affiliation: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou City, Zhejiang Province, China.
authors.forename: Fu-Rong
authors.initials: FR
authors.lastname: Tian
authors.affiliation: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou City, Zhejiang Province, China.
authors.forename: De-Li
authors.initials: DL
authors.lastname: ZhuGe
authors.affiliation: Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
authors.forename: Qi-Chuan
authors.initials: QC
authors.lastname: ZhuGe
authors.affiliation: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou City, Zhejiang Province, China.
authors.forename: Bi-Xin
authors.initials: BX
authors.lastname: Shen
authors.affiliation: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou City, Zhejiang Province, China.
authors.forename: Bing-Hui
authors.initials: BH
authors.lastname: Jin
authors.affiliation: WenZhou Chinese Medicine Hospital, WenZhou, Zhejiang Province, China.
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Huang
authors.affiliation: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou City, Zhejiang Province, China.
authors.forename: Ming-Ze
authors.initials: MZ
authors.lastname: Wu
authors.affiliation: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou City, Zhejiang Province, China.
authors.forename: Lu-Xin
authors.initials: LX
authors.lastname: Fan
authors.affiliation: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou City, Zhejiang Province, China.
authors.forename: Ying-Zheng
authors.initials: YZ
authors.lastname: Zhao
authors.affiliation: Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.|School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou City, Zhejiang Province, China.
authors.forename: He-Lin
authors.initials: HL
authors.lastname: Xu
mesh_terms: D000818:Animals; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage*; D005780:Gelatin / Q000008:administration & dosage*; D007150:Immunohistochemistry; D008863:Microspheres; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013119:Spinal Cord Injuries / Q000503:physiopathology*
chemical_list: D018696:Neuroprotective Agents; D016222:Fibroblast Growth Factor 2; D005780:Gelatin